AbbVie said a drug to treat blood cancer met its dual primary endpoints in a phase 3 study.

The company said etentamig demonstrated a significantly higher objective response rate and improvements in progression-free survival over standard available therapies in patients with triple-class exposed relapsed/refractory multiple myeloma.

AbbVie said it plans to discuss the results with global regulatory authorities to determine next steps.

"These results underscore our confidence in etentamig and our broader multiple myeloma strategy, which explores complementary T-cell engagers, targeted small molecules and rational combinations designed to address distinct disease mechanisms and patient needs over time," said AbbVie's therapeutic area head, oncology, solid tumor and hematology, Daejin Abidoye.